M
Max Jan
Researcher at Harvard University
Publications - 33
Citations - 3267
Max Jan is an academic researcher from Harvard University. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 11, co-authored 24 publications receiving 2386 citations. Previous affiliations of Max Jan include Princeton University & Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao,Ash A. Alizadeh,Chad Tang,June Helen Myklebust,June Helen Myklebust,Bindu Varghese,Saar Gill,Max Jan,Adriel C. Cha,Charles Chan,Brent T. Tan,Christopher Y. Park,Feifei Zhao,Holbrook E Kohrt,Raquel Malumbres,Javier Briones,Randy D. Gascoyne,Izidore S. Lossos,Ronald Levy,Irving L. Weissman,Ravindra Majeti +20 more
TL;DR: The eradication of human NHL solely with a monoclonal antibody therapy combining rituximab with a blocking anti-CD47 antibody, which synergized through a mechanism combining Fc receptor (FcR)-dependent and FcR-independent stimulation of phagocytosis that might be applicable to many other cancers.
Journal ArticleDOI
Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.
Max Jan,Thomas M. Snyder,M. Ryan Corces-Zimmerman,Paresh Vyas,Irving L. Weissman,Stephen R. Quake,Ravindra Majeti +6 more
TL;DR: This model in which AML develops by serial acquisition of mutations in long-lived self-renewing hematopoietic stem cells (HSCs) suggest the clonal evolution of AML genomes from founder mutations, revealing a potential mechanism contributing to relapse.
Journal ArticleDOI
Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
Mark P. Chao,Ash A. Alizadeh,Chad Tang,Max Jan,Rachel Weissman-Tsukamoto,Feifei Zhao,Christopher Y. Park,Irving L. Weissman,Ravindra Majeti +8 more
TL;DR: Preclinical support for the development of an anti-CD47 antibody therapy for treatment of human ALL is provided, and a blocking monoclonal antibody against CD47 enabled phagocytosis of ALL cells by macrophages in vitro and inhibited tumor engraftment in vivo.
Journal ArticleDOI
COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis
Levi B. Watkin,Birthe Jessen,Wojciech Wiszniewski,Timothy J. Vece,Max Jan,Youbao Sha,Maike Thamsen,Regie Lyn P. Santos-Cortez,Kwanghyuk Lee,Tomasz Gambin,Lisa R. Forbes,Christopher S. Law,Asbjørg Stray-Pedersen,Mickie H. Cheng,Emily M. Mace,Mark S. Anderson,Dongfang Liu,Ling Fung Tang,Sarah K. Nicholas,Karen Nahmod,George Makedonas,Debra Canter,Pui-Yan Kwok,John Hicks,Kirk D. Jones,Samantha Penney,Shalini N. Jhangiani,Michael Rosenblum,Sharon D. Dell,Michael Waterfield,Feroz R. Papa,Donna M. Muzny,Noah Zaitlen,Suzanne M. Leal,Claudia Gonzaga-Jauregui,Eric Boerwinkle,Eric Boerwinkle,N. Tony Eissa,Richard A. Gibbs,James R. Lupski,Jordan S. Orange,Anthony K. Shum +41 more
TL;DR: The findings uncover an unexpected molecular link between a vesicular transport protein and a syndrome of autoimmunity manifested by lung and joint disease.
Journal ArticleDOI
Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker
Max Jan,Mark P. Chao,Adriel C. Cha,Ash A. Alizadeh,Andrew J. Gentles,Irving L. Weissman,Ravindra Majeti +6 more
TL;DR: In this article, the identification of TIM3 as an AML stem cell surface marker more highly expressed on multiple specimens of acute myeloid leukemia (AML) LSC than on normal bone marrow HSC was reported.